Nelipepimut S

Drug Profile

Nelipepimut S

Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; Nelipepimut-S; NeuVax

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Breast cancer
  • Phase I Gastric cancer
  • Preclinical Bladder cancer; Ovarian cancer; Pancreatic cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 12 Jul 2017 Nelipepimut S is available for licensing as of 12 Jul 2017. https://www.galenabiopharma.com
  • 04 Apr 2017 Adverse events data from a phase II trial in Breast cancer presented at the American Association for Cancer Research-2017 (AACR-2017)
  • 30 Nov 2016 Galena Biopharma resumes enrolment a phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) in USA (Intradermal) (NCT02636582)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top